

PERTUZUMAB TRASTUZUMAB (Phesgo) SC (adjuvant after completion of neoadjuvant pertuzumab trastuzumab chemotherapy combination and surgery)

INDICATION (ICD10) C50

Check the most recent Blueteq eligibility criteria before prescribing Blueteq registration required. (www.england.nhs.uk/publication/national-cancer-drugs-fund-list/) (PER4a), (PER4b)

1. Pertuzumab in combination with intravenous trastuzumab as adjuvant therapy for patients with adequately excised, HER2-positive (HER2 3+) early breast cancer which was diagnosed as being NODE POSITIVE prior to neoadjuvant treatment and has now completed neoadjuvant pertuzumab in combination with trastuzumab and chemotherapy and surgery without progression. PS 0 or 1. (TA569)
2. Pertuzumab in combination with intravenous trastuzumab as adjuvant therapy for adequately excised, HER2-positive (HER2 3+) early breast cancer patients thought to be node negative or of unknown nodal status prior to neoadjuvant chemotherapy and found to be axillary node positive AFTER completion of neoadjuvant pertuzumab/trastuzumab and surgery without progression. PS 0 or 1. (TA569)

REGIMEN

Cycle 1 (loading dose)

Day 1 *PERTUZUMAB with TRASTUZUMAB 1800mg SC over 8 minutes
(if previous neoadjuvant dose <6 weeks ago reduce dose to 1200mg maintenance dose)
(1800mg equivalent to pertuzumab 1200mg and trastuzumab 600mg (1200/600mg vial)).

Cycle 2 onwards (maintenance doses)

Day 1 *PERTUZUMAB with TRASTUZUMAB 1200mg SC over 5 minutes
(1200mg equivalent to pertuzumab 600mg and trastuzumab 600mg (600/600mg vial)).

*For patients unable to receive SC pertuzumab / trastuzumab (phesgo) see the pertuzumab trastuzumab IV substitution regimen for IV pertuzumab plus IV trastuzumab doses, observation times etc.

Pertuzumab / Trastuzumab loading dose - observation time post injection 30 minutes

Pertuzumab / Trastuzumab maintenance doses - observation time post injection 15 minutes

CYCLE FREQUENCY AND NUMBER OF CYCLES

Every 21 days for **total** maximum 18 doses of pertuzumab and total maximum 18 doses trastuzumab including all the doses of pertuzumab and/or trastuzumab received as neoadjuvant treatment.

ie maximum 10 cycles of pertuzumab and trastuzumab following docetaxel carboplatin pertuzumab trastuzumab neoadjuvant regimen

maximum 12 cycles of pertuzumab and trastuzumab following anthracycline containing pertuzumab trastuzumab neoadjuvant regimen

ANTI-EMETICS

Minimal risk

CONCURRENT MEDICATION REQUIRED

Pertuzumab with Trastuzumab	Injection related chills and/or fevers – treat with paracetamol and chlorphenamine.
-----------------------------	---

INVESTIGATIONS

Blood results required before SACT administration

FBC, U&Es & LFTs 3 monthly

Baseline weight and 3 monthly weight.

Monitor cardiac function as per network policy. The left ventricular ejection fraction prior to commencing adjuvant cycles of pertuzumab plus trastuzumab remains $\geq 50\%$.

MAIN TOXICITIES AND ADVERSE REACTIONS

<p>Pertuzumab and trastuzumab</p>	<p>Cardiotoxicity - monitor cardiac function. Injection related chills, fevers or headache, slow the rate of injection or pause and appropriate medical therapies administered (Treatment including oxygen, beta agonists, antihistamines, rapid intravenous fluids and antipyretics may also help alleviate systemic symptoms.). For severe injection related reactions discontinue permanently. Other symptoms may include nausea, hypertension, vomiting, pain, rigors, headache, cough, dizziness, rash, and asthenia. Febrile neutropenia, diarrhea, pulmonary events Cardiomyopathy: Pertuzumab with trastuzumab administration can result in subclinical and clinical cardiac failure manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue pertuzumab with trastuzumab for cardiomyopathy.</p>
-----------------------------------	--

DOSE MODIFICATIONS

Pertuzumab with trastuzumab

Delay more than 6 weeks since last dose

The loading dose of pertuzumab and trastuzumab 1800mg SC (equivalent to pertuzumab 1200mg and trastuzumab 600mg (1200/600mg vial)) should be readministered for 1 dose then followed by maintenance doses of pertuzumab and trastuzumab 1200mg SC (equivalent to pertuzumab 600mg and trastuzumab 600mg (600/600mg vial)).

Non-haematological

Pertuzumab with Trastuzumab

Continuation and discontinuation of pertuzumab and trastuzumab based on interval LVEF assessment as per network guidelines

REFERENCES

1. Baselga, J et al; NEJM 2012; 366 (2): 109–119
2. Gianni, L et al; Lancet Oncology 2012; 13 (1): 25–32
3. Schneeweiss, A et al; Ann Oncol 2013; 24 (9): 2278–2284 (neo-adjuvant)
4. Jones, AL et al; Br J Cancer 2009; 100: 684–692
5. Von Minckwitz, G et al; NEJM 2017; 377: 122–131 (adjuvant)